Teleflex Study Shows 70% Reduction in CLABSI Risk with Arrowg+ard Technology — Teleflex Incorporated

Event summary

Teleflex's peer-reviewed study in the American Journal of Infection Control showed a 70% lower hazard of CLABSI with Arrowg+ard Technology compared to plain CVCs over a 30-day period.
The study involved 1,750 critically ill patients across six hospitals in four countries.
Arrowg+ard Technology demonstrated significant separation of infection-risk curves within 30 days of catheter insertion.
The study also found significantly lower mortality in the Arrowg+ard group (18.4%) compared to the plain CVC group (28.3%).
This study builds on a previous 2025 study that showed a 70.5% reduction in overall CLABSI incidence.

The big picture

Teleflex's study provides robust clinical evidence supporting the efficacy of its Arrowg+ard Technology in reducing CLABSI risk, a critical concern in healthcare settings. This reinforces Teleflex's position in the medical technology sector, particularly in infection prevention. The findings align with broader industry trends emphasizing evidence-based infection control strategies and could influence clinical practices globally.

What we're watching

Clinical Adoption: How quickly clinicians will adopt Arrowg+ard Technology given the strong clinical evidence.
Regulatory Impact: Whether the study results will influence international infection prevention guidelines.
Market Differentiation: The pace at which Teleflex can leverage this data to differentiate itself from competitors in the CVC market.